

**USE OF PROPARGYL GLYCINE AMINO PROPARGYL DIOL
COMPOUNDS FOR TREATMENT OF RENAL FAILURE**

RELATED APPLICATIONS

5 This application is a divisional of U.S. Application Serial No. 09/479,280, filed 6 January 2000, which issued as U.S. Patent No. 6,342,624, which is a continuation of Application Serial No. 09/969,522 filed on 13 November 1997, which is a 10 continuation of Application Serial No. 08/771,334, filed on 16 January 1996, which is a continuation of Application Serial No. 08/199,237, filed 28 February 1994, which issued 16 January 1996 as U.S. Patent 5,484,812, which is a continuation-in-part of Application Serial No. 07/784,272, filed on 29 October 1991, 15 which issued on 29 June 1993 as U.S. Patent 5,223,535.

FIELD OF THE INVENTION

20 Renin-inhibiting compounds are known for control of hypertension. Of particular interest herein are compounds useful as renin inhibiting agents.

BACKGROUND OF THE INVENTION

25 Renin is a proteolytic enzyme produced and secreted into the bloodstream by the juxtaglomerular cells of the kidney. In the bloodstream, renin cleaves a peptide bond in the serum protein angiotensinogen to produce a decapeptide known as angiotensin I. A second enzyme known as angiotensin converting 30 enzyme, cleaves angiotensin I to produce the octapeptide known as angiotensin II. Angiotensin II is a potent pressor agent responsible for vasoconstriction and elevation of cardiovascular pressure. Attempts have been made to control hypertension by blocking the action of renin or by blocking the formation of 35 angiotensin II in the body with inhibitors of angiotensin I converting enzyme.

40 Classes of compounds published as inhibitors of the action of renin on angiotensinogen include renin antibodies, pepstatin and its analogs, phospholipids, angiotensinogen analogs, pro-renin related analogs and peptide aldehydes.

115 141
~~PROPARGYL GLYCINE AMINO PROPARGYL DIOL COMPOUNDS
FOR TREATMENT OF HYPERTENSION~~

115 142
RELATED APPLICATION

5

This application is a continuation-in-part of U.S. Application Serial No. 07/784,272 filed 29 October 1991.

10
FIELD OF THE INVENTION

15
Renin-inhibiting compounds are known for control of hypertension. Of particular interest herein are compounds useful as renin inhibiting agents.

20
BACKGROUND OF THE INVENTION

25
Renin is a proteolytic enzyme produced and secreted into the bloodstream by the juxtaglomerular cells of the kidney. In the bloodstream, renin cleaves a peptide bond in the serum protein angiotensinogen to produce a decapeptide known as angiotensin I. A second enzyme known as angiotensin converting enzyme, cleaves angiotensin I to produce the octapeptide known as angiotensin II. Angiotensin II is a potent pressor agent responsible for vasoconstriction and elevation of cardiovascular pressure. Attempts have been made to control hypertension by blocking the action of renin or by blocking the formation of angiotensin II in the body with inhibitors of angiotensin I converting enzyme.

30
35
Classes of compounds published as inhibitors of the action of renin on angiotensinogen include renin antibodies, pepstatin and its analogs, phospholipids, angiotensinogen analogs, pro-renin related analogs and peptide aldehydes.

A peptide isolated from actinomyces has been reported as an inhibitor of aspartyl proteases such as pepsin, cathepsin D and renin [Umezawa et al, in J. Antibiot. (Tokyo), 23, 259-262 (1970)]. This peptide, known as pepstatin, was found to reduce blood pressure in vivo after the injection of hog renin into nephrectomized rats [Gross et al, Science, 175, 656 (1971)]. Pepstatin has the disadvantages of low solubility and of inhibiting acid proteases in addition to renin. Modified pepstatins have been synthesized in an attempt to increase the specificity for human renin over other physiologically important enzymes. While some degree of specificity has been achieved, this approach has led to rather high molecular weight hepta- and octapeptides [Boger et al, Nature, 303, 81 (1983)]. High molecular weight peptides are generally considered undesirable as drugs because gastrointestinal absorption is impaired and plasma stability is compromised.

Short peptide aldehydes have been reported as renin inhibitors [Kokubu et al, Biochim. Biophys. Res. Commun., 118, 929 (1984); Castro et al, FEBS Lett., 167, 273 (1984)]. Such compounds have a reactive C-terminal aldehyde group and would likely be unstable in vivo.

Other peptidyl compounds have been described as renin inhibitors. EP Appl. #128,762, published 18 December 1984, describes dipeptide and tripeptide glyco- containing compounds as renin inhibitors [also see Hanson et al, Biochm. Biophys. Res. Comm., 132, 155-161 (1985), 146, 959-963 (1987)]. EP Appl. #181,110, published 14 May 1986, describes dipeptide histidine derivatives as renin inhibitors. EP Appl. #186,977 published 9 July 1986 describes renin-inhibiting compounds containing an alkynyl moiety, specifically a propargyl glycine moiety, attached to the main chain

between the N-terminus and the C-terminus, such as N-[4(S)-[(N)-[bis(1-naphthylmethyl)acetyl]-DL-propargylglycylamino]-3(S)-hydroxy-6-methylheptanoyl]-L-isoleucinol. EP Appl. #189,203, published 30 July 1986, describes peptidyl-aminodiols as renin inhibitors. EP Appl. #200,406, published 10 December 1986, describes alkynaphthylmethylpropionyl-histidyl aminohydroxy alkanoates as renin inhibitors. EP Appl. #216,539, published 1 April 1987, describes

10 alkynaphthylmethylpropionyl aminoacyl aminoalkanoate compounds as renin inhibitors orally administered for treatment of renin-associated hypertension. EP Appl. #229,667, published 22 July 1987, describes acyl α-aminoacyl aminodiol compounds having a

15 piperazinylcarbonyl or an alkylaminoalkylcarbonyl terminal group at the N-amino acid terminus, such as 2(S)-{[(1-piperazinyl)carbonyl]-oxy}-3-phenylpropionyl)-Phe-His amide of 2(S)-amino-1-cyclohexyl-3(R), 4(S)-dihydroxy-6-methylheptane. PCT Application No. WO 20 87/04349, published 30 July 1987, describes

20 aminocarbonyl aminoacyl hydroxyether derivatives having an alkylamino-containing terminal substituent and which are described as having renin-inhibiting activity for use in treating hypertension. EP Appl. #300,189


25 published 25 January 1989 describes amino acid monohydric derivatives having an alkylamino-alkylamino N-terminus and a β-alanine-histidine or sarcosyl-histidine attached to the main chain between the N-terminus and the C-terminus, which derivatives are

30 mentioned as useful in treating hypertension. U.S. Patent No. 4,902,706 which issued 13 February 1990 describes a series of histidineamide-containing amino alkylaminocarbonyl-H-terminal aminodiol derivatives for use as renin inhibitors. U.S. Patent No. 5,032,577

35 which issued 16 July 1991 describes a series of histidineamide-aminodiol-containing renin inhibitors.

DESCRIPTION OF THE INVENTION


Propargyl glycine amino propargyl diol compounds, having utility as renin inhibitors for treatment of hypertension in a subject, constitute a family of compounds of general Formula I:



wherein A is selected from methylene, CO, SO and SO₂;
 wherein X is selected from oxygen atom, methylene and
~~>NR₁₀~~ with R₁₀ selected from hydrido, alkyl and benzyl;
 wherein each of R₁ and R₉ is a group independently selected from hydrido, alkyl, cycloalkyl, alkoxyacyl, haloalkyl, alkoxycarbonyl, benzyloxycarbonyl, loweralkanoyl, haloalkylacyl, phenyl, benzyl, naphthyl, and naphthylmethyl, any one of which groups having a substitutable position may be optionally substituted with one or more radicals selected from alkyl, alkoxy, alkenyl, alkynyl, halo, haloalkyl, cyano and phenyl, and wherein the nitrogen atom to which R₁ and R₉ are attached may be combined with oxygen to form an N-oxide; wherein R₂ is selected from hydrido, alkyl, dialkylaminoalkyl, alkylacylaminoalkyl, benzyl and cycloalkyl; wherein R₃ is selected from alkyl, cycloalkylalkyl, acylaminoalkyl, phenylalkyl, naphthylmethyl, aryl, heterocyclicalkyl and heterocycliccycloalkyl, wherein the cyclic portion of any of said phenylalkyl, naphthylmethyl, aryl, heterocyclicalkyl and heterocycliccycloalkyl groups may be substituted by one or more radicals selected from halo, hydroxy, alkoxy and alkyl; wherein each of R₄ and R₆ is independently selected from hydrido, alkyl, benzyl

P2676/1-54660

and cycloalkyl; wherein each of R₅ and R₈ is independently selected from




5

wherein V is selected from hydrido, alkyl, cycloalkyl, haloalkyl, benzyl and phenyl; wherein each of R₁₃ and R₁₄ is a radical independently selected from hydrido, alkyl, alkenyl, alkynyl, cycloalkyl, phenyl, heterocyclic, heterocyclicalkyl and heterocycliccycloalkyl; wherein R₇ is selected from substituted or unsubstituted alkyl, cycloalkyl, phenyl, cycloalkylalkyl and phenylalkyl, any one of which may be substituted with one or more groups selected from alkyl, hydroxy, alkoxy, halo, haloalkyl, alkenyl, alkynyl and cyano; wherein each of R₁₁ and R₁₂ is independently selected from hydrido, alkyl, haloalkyl, dialkylamino and phenyl; and wherein m is zero or one; wherein n is a number selected from zero through five; wherein p is a number selected from zero through five; and wherein q is a number selected from zero through five; or a pharmaceutically-acceptable salt thereof.

A preferred family of compounds consists of
25 compounds of Formula I wherein A is selected from methylene, CO, SO and SO₂; wherein X is selected from oxygen atom, methylene and >NR₁₀ with R₁₀ selected from hydrido, alkyl and benzyl; wherein each of R₁ and R₉ is independently selected from hydrido, lower alkyl,
30 haloalkyl, cycloalkyl, alkoxy carbonyl, benzyloxycarbonyl, lower alkanoyl, alkoxy acyl, phenyl and benzyl, and wherein the nitrogen atom to which R₁ and R₉

100-93-6 100-94-7 100-95-8


are attached may be combined with oxygen to form an N-oxide; wherein each of R₂, R₄ and R₆ is independently selected from hydrido and alkyl; wherein R₃ is selected from phenylalkyl, naphthylmethyl, cyclohexylalkyl,
5 cyclopentylalkyl, heteroarylalkyl and heteroarylalkylcycloalkyl; wherein each of R₅ and R₈ is independently selected from



10 wherein V is selected from hydrido, alkyl, haloalkyl, benzyl and phenyl; wherein each of R₁₃ and R₁₄ is a radical independently selected from hydrido, alkyl, alkenyl, alkynyl, cycloalkyl, heteroaryl,
15 heteroarylalkyl and heteroarylalkylcycloalkyl; wherein R₇ is selected from substituted or unsubstituted cyclohexylmethyl and benzyl, either one of which may be substituted with one or more groups selected from alkyl, hydroxy, alkoxy, halo and haloalkyl; wherein each of R₁₁ and R₁₂ is independently selected from hydrido, alkyl, dialkylamino and phenyl; wherein m is zero or one;
20 wherein n is a number selected from zero through five; wherein p is a number selected from zero through five; and wherein q is a number selected from zero through five; or a pharmaceutically-acceptable salt thereof.

A more preferred family of compounds consists of compounds of Formula I wherein A is selected from methylene, CO, SO and SO₂; wherein X is selected from
30 oxygen atom, methylene and >NR₁₀ with R₁₀ selected from hydrido, alkyl and benzyl; wherein each of R₁ and R₉ is independently selected from hydrido, alkyl, alkoxyacyl,

haloalkyl, alkoxy carbonyl, benzyloxycarbonyl, and benzyl, and wherein the nitrogen atom to which R₁ and R₉ are attached may be combined with oxygen to form an N-oxide; wherein each of R₂, R₄ and R₆ is independently selected from hydrido and alkyl; wherein R₃ is selected from benzyl, phenethyl, cyclohexylmethyl, phenpropyl, pyrrolidinyl, piperidinyl, pyrrolidinylmethyl, piperidinylmethyl, pyrazolemethyl, pyrazoleethyl, pyridylmethyl, pyridylethyl, thiazolemethyl, thiazoleethyl, imidazolemethyl, imidazoleethyl, thienylmethyl, thienylethyl, furanylmethyl, furanylethyl, oxazolemethyl, oxazoleethyl, isoxazolemethyl, isoxazoleethyl, pyridazinemethyl, pyridazineethyl, pyrazinemethyl and pyrazineethyl; wherein each of R₅ and R₈ is independently selected from




wherein V is selected from hydrido, alkyl and haloalkyl; wherein each of R₁₃ and R₁₄ is a radical independently selected from hydrido, alkyl, alkenyl, alkynyl, thiazole and thiazolemethyl; wherein R₇ is cyclohexylmethyl; wherein each of R₁₁ and R₁₂ is independently selected from hydrido, alkyl, dialkylamino and phenyl; wherein m is zero or one; wherein n is a number selected from zero through five; wherein p is a number selected from zero through five; and wherein q is a number selected from zero through five; or a pharmaceutically-acceptable salt thereof.

30


An even more preferred family of compounds consists of compounds Formula I wherein A is selected from CO and SO₂; wherein X is selected from oxygen atom,

methylene and NR_{10} with R₁₀ selected from hydrido and methyl; wherein each of R₁ and R₉ is independently selected from hydrido, lower alkyl, alkoxyacetyl, alkoxycarbonyl, benzyloxycarbonyl, haloalkyl and benzyl,
 5 and wherein the nitrogen atom to which R₁ and R₉ are attached may be combined with oxygen to form an N-oxide; wherein R₂ is selected from hydrido, methyl, ethyl and isopropyl; wherein R₃ is selected from benzyl, phenethyl, cyclohexylmethyl, pyrrolidinyl, piperidinyl,
 10 pyrrolidinylmethyl, piperidinylmethyl, pyrazolemethyl, pyrazoleethyl, pyridylmethyl, pyridylethyl, thiazolemethyl, thiazoleethyl, imidazolemethyl, imidazoleethyl, thiethylmethyl, thiethyl, furanylmethyl, furanylethyl, oxazolemethyl,
 15 oxazoleethyl, isoxazolemethyl, isoxazoleethyl, pyridazinemethyl, pyridazineethyl, pyrazinemethyl and pyrazineethyl; wherein each of R₄ and R₆ is independently selected from hydrido and methyl; wherein each of R₅ and R₈ is independently selected from
 20



wherein V is selected from hydrido, alkyl and trifluoromethyl; wherein each of R₁₃ and R₁₄ is a radical independently selected from hydrido, alkyl and alkynyl; wherein R₇ is cyclohexylmethyl; wherein each of R₁₁ and R₁₂ is independently selected from hydrido, alkyl, dialkylamino and phenyl; wherein m is zero; wherein n is a number selected from zero through five;
 25 wherein p is a number selected from zero through five; and wherein q is a number selected from zero through five; or a pharmaceutically-acceptable salt thereof.

A highly preferred family of compounds consists of compounds of Formula I wherein A is selected from CO and SO₂; wherein X is selected from oxygen atom and methylene; wherein each of R₁ and R₉ is independently selected from hydrido, methyl, ethyl, n-propyl, isopropyl, benzyl, b, b, b-trifluoroethyl, t-butyloxycarbonyl and methoxymethylcarbonyl, and wherein the nitrogen atom to which R₁ and R₉ are attached may be combined with oxygen to form an N-oxide; wherein R₂ is selected from hydrido, methyl, ethyl and isopropyl; wherein R₃ is selected from benzyl, cyclohexylmethyl, phenethyl, pyrazolemethyl, pyrazoleethyl, pyridylmethyl, pyridylethyl, thiazolemethyl, thiazoleethyl, imidazolemethyl, imidazoleethyl, thiethylmethyl, thienelethyl, furanylmethyl, furanylethyl, oxazolemethyl, oxazoleethyl, isoxazolemethyl, isoxazoleethyl, pyridazinemethyl, pyridazineethyl, pyrazinemethyl and pyrazineethyl; wherein each of R₅ and R₈ is independently selected from




wherein V is selected from hydrido, alkyl and trifluoromethyl; wherein each of R₁₃ and R₁₄ is a radical independently selected from hydrido, methyl, ethyl, propyl and ethynyl; wherein R₇ is cyclohexylmethyl; wherein each of R₄ and R₆ is independently selected from hydrido and methyl; wherein each of R₁₁ and R₁₂ is independently selected from hydrido, alkyl, dialkylamino and phenyl; wherein m is zero; wherein n is a number selected from zero through

five; wherein p is a number selected from zero through five; and wherein q is a number selected from zero through five; or a pharmaceutically-acceptable salt thereof.

5

A more highly preferred class of compounds consists of compounds of Formula I wherein A is selected from CO and SO₂; wherein X is selected from oxygen atom and methylene; wherein each of R₁ and R₉ is a group independently selected from hydrido, methyl, ethyl, n-propyl, isopropyl, benzyl, b, b, b-trifluoroethyl, t-butyloxycarbonyl and methoxymethylcarbonyl, and wherein the nitrogen atom to which R₁ and R₉ are attached may be combined with oxygen to form an N-oxide; wherein R₂ is selected from hydrido, methyl, ethyl and isopropyl; wherein R₃ is selected from benzyl, cyclohexylmethyl, phenethyl, imidazolemethyl, pyridylmethyl and 2-pyridylethyl; wherein each of R₅ and R₈ is independently selected from

FEBRUARY 22, 1960
RECEIVED
U.S. PATENT OFFICE
SEARCHED
INDEXED
FILED

wherein V is selected from hydrido, alkyl and trifluoromethyl; wherein each of R₁₃ and R₁₄ is a radical independently selected from hydrido, methyl and ethynyl; wherein R₇ is cyclohexylmethyl; wherein each of R₄ and R₆ is independently selected from hydrido and methyl; wherein each of R₁₁ and R₁₂ is independently selected from hydrido, alkyl and phenyl; wherein m is zero; wherein n is a number selected from zero through three; wherein p is a number selected from one through three; and wherein q is zero or one; or a pharmaceutically-acceptable salt thereof.

The term "hydrido" denotes a single hydrogen atom (H). This hydrido group may be attached, for example, to an oxygen atom to form a hydroxyl group; or, 5 as another example, one hydrido group may be attached to a carbon atom to form a >CH- group; or, as another example, two hydrido groups may be attached to a carbon atom to form a -CH₂- group. Where the term "alkyl" is used, either alone or within other terms such as 10 "haloalkyl" and "hydroxyalkyl", the term "alkyl" embraces linear or branched radicals having one to about twenty carbon atoms or, preferably, one to about twelve carbon atoms. More preferred alkyl radicals are "lower alkyl" radicals having one to about ten carbon atoms. 15 Most preferred are lower alkyl radicals having one to about six carbon atoms. The term "cycloalkyl" embraces cyclic radicals having three to about ten ring carbon atoms, preferably three to about six carbon atoms, such as cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl. 20 The term "haloalkyl" embraces radicals wherein any one or more of the alkyl carbon atoms is substituted with one or more halo groups, preferably selected from bromo, chloro and fluoro. Specifically embraced by the term "haloalkyl" are monohaloalkyl, dihaloalkyl and 25 polyhaloalkyl groups. A monohaloalkyl group, for example, may have either a bromo, a chloro, or a fluoro atom within the group. Dihaloalkyl and polyhaloalkyl groups may be substituted with two or more of the same halo groups, or may have a combination of different halo 30 groups. A dihaloalkyl group, for example, may have two fluoro atoms, such as difluoromethyl and difluorobutyl groups, or two chloro atoms, such as a dichloromethyl group, or one fluoro atom and one chloro atom, such as a fluoro-chloromethyl group. Examples of a polyhaloalkyl 35 are trifluoromethyl, 1,1-difluoroethyl, 2,2,2-trifluoroethyl, perfluoroethyl and 2,2,3,3-tetrafluoropropyl groups. The term "difluoroalkyl"

RECORDED BY
SHELDON STONE

embraces alkyl groups having two fluoro atoms substituted on any one or two of the alkyl group carbon atoms. The terms "alky lol" and "hydroxyalkyl" embrace linear or branched alkyl groups having one to about ten 5 carbon atoms any one of which may be substituted with one or more hydroxyl groups. The term "alkenyl" embraces linear or branched radicals having two to about twenty carbon atoms, preferably three to about ten carbon atoms, and containing at least one carbon-carbon 10 double bond, which carbon-carbon double bond may have either cis or trans geometry within the alkenyl moiety. The term "alkynyl" embraces linear or branched radicals having two to about twenty carbon atoms, preferably two to about ten carbon atoms, and containing at least one carbon-carbon triple bond. The term "cycloalkenyl" 15 embraces cyclic radicals having three to about ten ring carbon atoms including one or more double bonds involving adjacent ring carbons. The terms "alkoxy" and "alkoxyalkyl" embrace linear or branched oxy-containing radicals each having alkyl portions of one to about ten carbon atoms, such as methoxy group. The term "alkoxyalkyl" also embraces alkyl radicals having two or more alkoxy groups attached to the alkyl radical, that 20 is, to form monoalkoxyalkyl and dialkoxyalkyl groups. The "alkoxy" or "alkoxyalkyl" radicals may be further substituted with one or more halo atoms, such as fluoro, chloro or bromo, to provide haloalkoxy or 25 haloalkoxyalkyl groups. The term "alkylthio" embraces radicals containing a linear or branched alkyl group, of one to about ten carbon atoms attached to a divalent 30 sulfur atom, such as a methylthio group. Preferred aryl groups are those consisting of one, two, or three benzene rings. The term "aryl" embraces aromatic radicals such as phenyl, naphthyl and biphenyl. The 35 term "aralkyl" embraces aryl-substituted alkyl radicals such as benzyl, diphenylmethyl, triphenylmethyl, phenylethyl, phenylbutyl and diphenylethyl. The terms

"benzyl" and "phenylmethyl" are interchangeable. The terms "aryloxy" and "arylthio" denote radical respectively, aryl groups having an oxygen or sulfur atom through which the radical is attached to a nucleus, examples of which are phenoxy and phenylthio. The terms "sulfinyl" and "sulfonyl", whether used alone or linked to other terms, denotes respectively divalent radicals SO and SO₂. The term "aralkoxy", alone or within another term, embraces an aryl group attached to an alkoxy group to form, for example, benzyloxy. The term "acyl" whether used alone, or within a term such as acyloxy, denotes a radical provided by the residue after removal of hydroxyl from an organic acid, examples of such radical being acetyl and benzoyl. "Lower alkanoyl" is an example of a more preferred sub-class of acyl. The term "amido" denotes a radical consisting of nitrogen atom attached to a carbonyl group, which radical may be further substituted in the manner described herein. The amido radical can be attached to the nucleus of a compound of the invention through the carbonyl moiety or through the nitrogen atom of the amido radical. The term "alkenylalkyl" denotes a radical having a double-bond unsaturation site between two carbons, and which radical may consist of only two carbons or may be further substituted with alkyl groups which may optionally contain additional double-bond unsaturation.

The term "heterocyclic", as used alone or within groups such as "heterocyclicalkyl" and "heterocycliccycloalkyl", (hereinafter referred to as "heterocyclic-containing groups"), embraces radicals having a saturated, or partially unsaturated, or fully saturated heterocyclic group, wherein the cyclic portion consists of a ring system having one ring or two fused rings, which ring system contains one, two or three hetero atoms as ring members selected from nitrogen, oxygen and sulfur atoms, and which ring system has 4 to

about 12 ring members. Examples of saturated heterocyclic-containing groups are pyrrolidinyl, piperidinyl, pyrrolidinylmethyl, piperidinylmethyl, pyrrolidinylcyclopropyl and piperidinylcyclopropyl. The term "heteroaryl", whether used alone or within the greater terms "heteroarylalkyl" or "heteroarylcloalkyl", denotes a subset of "heterocyclic-containing groups" having a cyclic portion which is fully-unsaturated, that is, aromatic in character, and which has one or two hetero atoms as ring members, said hetero atoms selected from oxygen, sulfur and nitrogen atoms, and which ring system has five or six ring members. The "heteroaryl" ring may be attached to a linear or branched alkyl radical having one to about ten carbon atoms or may be attached to a cycloalkyl radical having three to about nine carbon atoms. Examples of such heteroarylalkyl or heteroarylcloalkyl groups are pyrazolemethyl, pyrazoleethyl, pyridylmethyl, pyridylethyl, thiazolemethyl, thiazoleethyl, imidazolemethyl, imidazoleethyl, thienylmethyl, thienylethyl, furanylmethyl, furanylethyl, oxazolemethyl, oxazoleethyl, thiazollycyclopropyl, imidazolecyclopropyl, thienylcyclopropyl, isoxazolemethyl, isoxazoleethyl, pyridazinemethyl, pyridazineethyl, pyrazinemethyl and pyrazineethyl. The "heterocyclic" portion or "heteroaryl" portion of the radical, as well as the alkyl or cycloalkyl portion of groups containing a "heterocyclic" or "heteroaryl" portion, may be substituted at a substitutable position with one or more groups selected from oxo, alkyl, alkoxy, halo, haloalkyl, cyano, aralkyl, aralkoxy, aryl and aryloxy. Such "heterocyclic", "heterocyclic"-containing group, or "heteroaryl" group may be attached as a substituent through a carbon atom of the hetero ring system, or may be attached through a carbon atom of a moiety substituted on a hetero ring-member carbon.

atom, for example, through the methylene substituent of an imidazolemethyl moiety. Also, a heterocyclic or heterocyclic-containing group may be attached through a ring nitrogen atom. For any of the foregoing defined 5 radicals, preferred radicals are those containing from one to about fifteen carbon atoms.

Specific examples of alkyl groups are methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, n-pentyl, isopentyl, methylbutyl, dimethylbutyl and neopentyl. Typical alkenyl and alkynyl groups may have one unsaturated bond, such as an allyl group, or may have a plurality of unsaturated bonds, with such plurality of bonds either adjacent, such as allene-type structures, or in conjugation, or separated by several saturated carbons.

卷之三


Also included in the family of compounds of Formula I are isomeric forms, including diastereoisomers, and the pharmaceutically-acceptable salts thereof. The term "pharmaceutically-acceptable salts" embraces salts commonly used to form alkali metal salts and to form addition salts of free acids or free bases. The nature of the salt is not critical, provided that it is pharmaceutically-acceptable. Suitable pharmaceutically-acceptable acid addition salts of compounds of Formula I may be prepared from an inorganic acid or from an organic acid. Examples of such inorganic acids are hydrochloric, hydrobromic, hydroiodic, nitric, carbonic, sulfuric and phosphoric acid. Appropriate organic acids may be selected from aliphatic, cycloaliphatic, aromatic, araliphatic, heterocyclic, carboxylic and sulfonic classes of organic acids, example of which are formic, acetic, propionic, succinic, glycolic, gluconic, lactic, malic, tartaric, citric, ascorbic, glucuronic, maleic, fumaric, pyruvic, aspartic, glutamic, benzoic, anthranilic, p-hydroxybenzoic, salicyclic, phenylacetic, mandelic, embonic (pamoic), methansulfonic, ethanesulfonic, 2-hydroxyethanesulfonic, pantothenic, benzenesulfonic, toluenesulfonic, sulfanilic, mesylic, cyclohexylaminosulfonic, stearic, algenic, b-hydroxybutyric, malonic, galactaric and galacturonic acid. Suitable pharmaceutically-acceptable base addition salts of compounds of Formula I include metallic salts made from aluminium, calcium, lithium, magnesium, potassium, sodium and zinc or organic salts made from N,N'-dibenzylethylenediamine, chloroprocaine, choline, diethanolamine, ethylenediamine, meglumine (N-methylglucamine) and procaine. Also included within the phrase "pharmaceutically-acceptable salts" are "quaternary" salts or salts of "onium" cations, such as ammonium, morpholinium and piperazinium cations, as well as any substituted derivatives of these cations where

the salt is formed on the nitrogen atom lone pair of electrons. All of these salts may be prepared by conventional means from the corresponding compound of Formula I by reacting, for example, the appropriate acid or base with the compound of Formula I.

Compounds of Formula I would be useful to treat various circulatory-related disorders. As used herein, the term "circulatory-related" disorder is intended to embrace cardiovascular disorders and disorders of the circulatory system, as well as disorders related to the circulatory system such as ophthalmic disorders including glaucoma. In particular, compounds of Formula I would be useful to inhibit enzymatic conversion of angiotensinogen to angiotensin I. When administered orally, a compound of Formula I would be expected to inhibit plasma renin activity and, consequently, lower blood pressure in a patient such as a mammalian subject (e.g., a human subject). Thus, compounds of Formula I would be therapeutically useful in methods for treating hypertension by administering to a hypertensive subject a therapeutically-effective amount of a compound of Formula I. The phrase "hypertensive subject" means, in this context, a subject suffering from or afflicted with the effects of hypertension or susceptible to a hypertensive condition if not treated to prevent or control such hypertension. Other examples of circulatory-related disorders which could be treated by compounds of the invention include congestive heart failure, renal failure and glaucoma.

Description of the Synthetic Methods for the Preparation of the Renin Inhibitors of the Invention

Synthetic Scheme 1




Synthetic Scheme 1
(Preparation of Compounds of Formula I)

A suitably protected amino aldehyde 1 is
5 treated with a Grignard reagent or other organometallic
reagent, preferably vinylmagnesium bromide, to obtain
the vinyl carbinol 2. This material, suitably
protected, is oxidized, preferably with ozone, followed
by dimethyl sulfide or zinc treatment, to give
10 intermediate 3. The preceeding process is exemplified in
Hanson, et al., J. Org. Chem. 50, 5399 (1985). This
aldehyde is reacted with an organometallic reagent such
as propargylmagnesium bromide to give intermediate 4.
Other suitable organometallic reagents include
15 ethynylmagnesium bromide, 1-methylpropynylmagnesium
bromide, 3-methylpropynyl-magnesium bromide,
butynylmagnesium bromide and pentynylmagnesium bromide,
but the choices are not limited to these reagents.
Compound 4 is deprotected then coupled, using standard
20 amide/peptide coupling methodology to protected triple
bond-containing (ethynyl) amino acid derivatives 5 to
give compound 6. These standard coupling procedures such
as the carbodiimide, active ester
(N-hydroxysuccinimide), and mixed carbonic anhydride
25 methods are shown in Benoiton, et al. J. Org. Chem. 48,
2939 (1983) and Bodansky, et al. "Peptide Synthesis",
Wiley (1976). Ethynyl-containing amino acid derivatives
may be prepared by using procedures such as found in
Schollkopf, Tetrahedron 39, 2085 (1983). Intermediate 6
30 is then deprotected, then coupled to intermediate 7
using the standard amide/peptide coupling methodology,
to give compounds of Formula I. Suitable protecting
groups may be selected from among those reviewed by R.
Geiger in "The Peptides", Academic Press, N.Y. vol. 2
35 (1979). For example, P₁ may by Boc or Cbz; P₂ may be a
typical oxygen protective group such as acetyl or t-
butyldimethylsilyl.

Synthetic Scheme 2

Preparation of 7:



5


Synthetic Scheme 2 (Preparation of Compounds of Formula I)

Intermediate 7 may be prepared according to the schematic of Synthetic Scheme 2. Intermediate 7 is prepared by coupling amine 8 to mono-protected carboxylic acid 9. Carboxylic acid 9 is a mono-activated moiety by virtue of a suitable leaving group Q which may be chloride, bromide, fluoride, N-hydroxysuccinimido, p-toluenesulfonyloxy or 15 isobutyloxycarbonyloxy, but is not limited to these groups. After coupling, protecting group P_4 is removed (if P_4 is a benzyl group, hydrogenolysis over palladium-on-carbon (Pd-C) is performed) to give intermediate amino acid 7.


090533-142304

Synthetic Scheme 3

Preparation of Intermediate 8




Preparation of 8, a non-cyclized diamine:




Preparation of 8:


8a:




1. Dibal
2. methylamine,
Pd-C, hydrogen
3. HCl, dioxane




8b:




1. Dibal
2. methylamine,
Pd-C, hydrogen



8c:



1. Dibal
2. methylamine,
Pd-C, hydrogen
3. Cbz-Cl
4. HCl, dioxane
5. HCO2H, CH2O
6. hydrog n, Pd-C



Synthetic Scheme 3
(Preparation of Compounds of Formula I)

Synthetic Scheme 3 describes the preparation
5 of intermediate 8, a non-cyclic diamine. Many of the
members of this class, such as ethylene diamine, N,N,N'-
trimethylethylene diamine, N,N'-dimethylethylene
diamine, N,N'-dimethylpropylene diamine, etc. are
commercially available starting materials. Other
10 substituted diamines such as compounds 8a through 8c are
obtainable by the procedures depicted in Scheme 3. For
example, Boc-L-alanine methyl ester is reduced with
diisobutylaluminum hydride to give the corresponding
aldehyde which is then reductively aminated with
15 methylamine, then the Boc group is cleaved to give 8a.
Alternatively, the procedure of Miller, et al. J. Med.
Chem. 19, 1382 (1976) may be employed to give
intermediate 8. In another example, a suitably protected
20 diamine is treated with trifluoroacetaldehyde in the
presence of sodium cyanoborohydride to give an
trifluoroethyl substituent on nitrogen, followed by
deprotection to give amine 8.

Abbreviations used:

25 P1 is an N-protecting group; P2 is H or an
oxygen protecting group; P3 is an N-protecting group;
P4 is an oxygen protecting group such as benzyl or
methyl; Q is a leaving group; Boc is t-
30 butyloxycarbonyl; Cbz is carbobenzoxy.

The following Steps 1-15 constitute specific exemplification of methods to prepare starting materials and intermediates embraced by the foregoing generic synthetic schemes. Those skilled in the art will readily understand that known variations of the conditions and processes of the following preparative procedures can be used to prepare the compounds of Steps 1-15. All temperatures expressed are in degrees Centigrade.

Compounds of Examples 1-99 may be prepared by using the procedures described in the following Steps 1-15:

卷之三

Step 1

5 (3S,4S)-N-[(tert-butyloxyl) carbonyl]-4-amino-3-(triisopropylsilyloxy)-5-phenylpentene

A solution of (3S,4S)-N-[(tert-butyloxyl) carbonyl]-4-amino-3-hydroxy-5-phenylpentene (36.1 mmol), imidazole (90.1 mmol),
10 chlorotriisopropylsilane (43.3 mmol) and DMF was stirred overnight at room temperature. H₂O (500ml) was added. The solution was extracted with Et₂O (2x250 mL). The combined organic material was washed with H₂O (250 mL), 0.5 M citric acid solution (2x120 mL), dilute KHCO₃ (2x100 mL), and brine (2x100 mL) and then dried with MgSO₄. The solvent was evaporated and the residue chromatographed on silica gel to give the title alcohol (12.9 g, 82% yield) ¹H, ¹³C, and APT NMR spectral data were consistent with the proposed structure.

Step 2

25 (2R,3S)-N-[(tert-butyloxyl) carbonyl]-3-amino-2-(triisopropylsilyloxy)-4-phenyl-1-butanol

Ozone was bubbled into a solution of the silyl allylic alcohol of Step 1 in CH₂Cl₂ (244 mL) and MeOH (81 mL) at -78°C until a blue color persisted. The excess ozone was removed with oxygen. To the -78°C
30 solution, sodium borohydride (80.5 mmol) was added. The mixture was stirred at -78°C for 3 h and then warmed to room temperature and H₂O (200 mL) was added. The solution was extracted with Et₂O (3x120 mL). The combined organic layers were washed with brine (2x100 mL) and then dried over Na₂SO₄. The filtrate was concentrated to give the title alcohol (13.06g, 100%

yield). The ^1H , ^{13}C , and APT NMR spectral data were consistent with the proposed structure.

Anal. calcd.: C, 63.76; H, 9.43; N, 3.54.
Found: C, 62.92; H, 9.23; N, 3.47.

5

Step 3

(2R,3S)-N-[tert-butyloxy]carbonyl-3-amino-2-(triisopropylsilyloxy)-4-cyclohexyl-1-butanol

The monosilylated diol of Step 2 was hydrogenated with 5% Rh-C at 60 psi and 60°C in MeOH (135 mL). The mixture was filtered and the filtrate evaporated. The residue was purified by chromatography, eluting with (15% EtOAc in hexane) to give the title alcohol (8.70g, 67% yield, mp 61-63°C). The ^1H , ^{13}C , and APT NMR spectral data were consistent with the proposed product.

Anal. calcd.: C, 64.96; H, 11.13; N, 3.16.
Found: C, 65.16; H, 11.26; N, 3.12.

Step 4

(2R,3S)-N-[tert-butyloxy]carbonyl-3-amino-2-(triisopropylsilyloxy)-4-cyclohexyl-1-butanal

To a -78°C solution of oxalyl chloride (10.8 mmol) in tetrahydrofuran (45 mL) was added dimethylsulfoxide (21.6 mmol). After stirring for 10 minutes, a solution of the title alcohol of Step 3 (10.8 mmol) in tetrahydrofuran (4.6 mL) was added dropwise. The solution was stirred for 20 minutes at -78°C and then Et₃N (45.1 mmol) was added. The reaction solution was allowed to warm to room temperature over a 2 hour period. The opaque, white mixture was poured into water (50 mL) and then extracted with ether (2x50mL). The

combined organic layer was washed with 1N HCl (50 mL), aqueous 5% NaHCO₃ (50 mL), and brine (50 mL). The dried filtrate (MgSO₄) was evaporated to give the title aldehyde (4.20g, 100% yield). The ¹H, ¹³C and APT NMR spectral data were consistent with the proposed structure.

Step 5

10 (4RS,5R,6S)-N-[tert-butyloxycarbonyl]-6-amino-5-
(triisopropylsilyloxy)-7-cyclohexyl-1-heptyn-4-ol

To a solution of magnesium metal (16.4 mmol) and HgCl₂ (0.03g) in Et₂O (4 mL) in a flask at room temperature was added several drops of 80% propargyl bromide (16.4 mmol) solution in toluene (1.82 mL) contained in an addition funnel. The mixture turned cloudy. Ether (10 mL) was then added to both the flask and to the propargyl bromide solution in the addition funnel. The funnel solution was added dropwise to the reaction mixture which was cooled to 10°C. The white opaque mixture was stirred for 45 minutes at room temperature after the addition was completed. A solution of the title aldehyde of Step 4 (4.64 mmol) in Et₂O (10 mL) was added dropwise to the flask at room temperature. After 2h at room temperature, the mixture was cooled down to 0°C and a saturated NH₄Cl solution (25 mL) was added. The Et₂O layer was collected and the aqueous layer was extracted with Et₂O (10 mL). The combined organic layers were washed with water (10mL), brine (10 mL) and then dried over MgSO₄. After evaporation, the residue (a clear, yellow liquid) was purified by medium column chromatography (10% EtOAc in hexane) to give the title alkyne (1.49g, 66.5% yield). The ¹H, ¹³C and APT NMR spectral data were consistent for the proposed structure.

st p 6

(4S,5R,6S)-N-[tert-butyloxylcarbonyl]-6-(amino)-4,5-dihydroxy-7-cyclohexyl-1-heptyne

5

A 1.0M tetra n-butylammonium fluoride solution (21.5 mmol) in THF (21.5mL) was added dropwise to the title alkyne of Step 5 (5.41 mmol) at room temperature. Thin-layer chromatography (TLC) (20% EtOAc in hexane) showed the reaction was completed in 1h. The solution was concentrated and EtOAc (160 mL) was added. The solution was washed with H₂O (3x60 mL), brine (100 mL), and then dried over MgSO₄. After evaporation, the residue (a clear, yellow liquid) was purified by column chromatography and the diastereomers were separated. The major isomer (Rf 0.16, 1.76g, 53% yield) was consistent with the proposed structure from ¹H, ¹³C and APT NMR spectral data.

Anal. calcd.: C, 66.43; H, 9.60; N, 4.30.
20 Found C, 66.00; H, 9.70; N, 4.20.

Step 7

(4S,5R,6S)-6-amino-7-cyclohexyl-4,5-dihydroxy-1-heptyne

To a solution of the diol heptyne of Step 6 isomer (2.85 mmol) in CH₂Cl₂ (5.5 mL) was added trifluoroacetic acid (71.3 mmol). The reaction was monitored by TLC (50% EtOAc in hexane). After 30 minutes the solution was concentrated and an aqueous 1.0N NaOH solution (7 mL) was added. The solution was extracted with EtOAc (4x10 mL). The organic layer was dried with MgSO₄. The filtrate was concentrated to give the title amine as a white sticky solid (0.67g, 100% yield). The ¹H, ¹³C and APT NMR spectral data were consistent with the prepared structure.

Anal. calc.: C, 68.68; H, 11.08; N, 6.16.
Found C, 67.58; H, 10.94; N, 5.95.

Step 8L-Boc-C-propargylglycine

5

L-C-propargylglycine (10g) [prepared by the method of Schwyzer et al., Helv. Chim. Acta (1976) 59, 2181] was suspended in tetrahydrofuran (30mL). Water (30mL), potassium carbonate (36.7g), and di-*tert*-butyl-dicarbonate (21.9g) were added. Additional water was added to produce a solution which was stirred for 12 hours at room temperature. The organic solvent was then evaporated and the aqueous solution was washed with ether, then acidified to pH 3 with 1N aqueous citric acid. The solution was extracted with methylene chloride and the solvent evaporated to give the title compound (18.9g, 97% yield), used without further purification.

Step 9

20

L-Boc-C-propargylglycine amide of (4S,5R,6S)-6-amino-7-cyclohexyl-4,5-dihydroxyhept-1-yne:

25

L-Boc-C-propargylglycine (1.2g) was dissolved in methylene chloride (5 mL) and N-methyl piperidine (0.57g) was added. The mixture was cooled to zero degrees centigrade and isobutyl chloroformate (0.78g) was added. The mixture was stirred for 10 minutes whereupon the title compound of Step 7 (1.4g) in methylene chloride (5 mL) and *tert*-butyl alcohol (5mL) was added and this mixture stirred for 15 minutes at 0°C and 4°C for 12 hours. The reaction mixture was washed successively with 1N citric acid, saturated sodium hydrogen carbonate, water and brine. The organic layer was dried over magnesium sulfate and evaporated to dryness. The residue was chromatographed on silica gel to give the title compound as a colorless oil. 300 MHz ¹H NMR: consistent with proposed structure.

Step 10

5 L-C-propargylglycine amide of (4S,5R,6S)-6-amino-7-
cyclohexyl-4,5-dihydroxyhept-1-yne:

The title compound of Step 9 (0.76g) was dissolved in a mixture of trifluoroacetic acid (4.9 mL) and methylene chloride (4.9 mL), and stirred for 30 minutes at room temperature. The solvent was then evaporated and the residue taken up in ethyl acetate. The organic layer was washed with saturated sodium hydrogen carbonate, water and brine, then dried over magnesium sulfate and evaporated to give the title amine.

10 300 MHz ^1H NMR: consistent with proposed structure.

15

Step 11

20 2R-Benzyl butanedioic acid, 1-benzyl ester,
dicyclohexylammonium salt

To a slurry of 4-(4-methoxybenzyl) itaconate (prepared by the method of Talley in US Patent # 4,939,288) (50g) in toluene (250mL) was added 1,8-25 diazabicyclo[5.4.0]undec-7-ene (DBU, 30.4g) in one portion. Then a solution of benzyl bromide (34.2g) in toluene (50mL) was added dropwise over 0.5 hour. The reaction was stirred for 0.5 hour at room temperature and then poured into a separatory funnel. The mixture was 30 washed with 3N HCl, aqueous sodium bicarbonate, brine and dried over magnesium sulfate. The solvent was evaporated to give a clear mobile liquid (68g). Chromatography on silica gel, eluting with from 100% hexane to 25% ethyl acetate gave pure 1-(benzyl)-4-(4-methoxybenzyl) 35 itaconate (55g, 81% yield). A large Fisher-Porter bottle was charged with this itaconate (41g), triethylamine (36g), palladium acetate (380mg), tri-o-tolylphosphine (1.04g) and iodobenzene (24.7g). The bottle was sealed and flushed with nitrogen and placed in an oil bath and

heated for 70 minutes. The residue was chromatographed on silica gel, eluting with 100% hexanes until the less polar impurities were removed. Eluting with 10% ethyl acetate in hexane gave the pure phenyl itaconate. This compound (23.8g) was mixed with toluene (200mL) and the resulting solution treated with trifluoroacetic acid (30mL). The solution was stirred at room temperature for 1.5 hour and then evaporated. The residue was taken up in ether (150mL) and treated with dicyclohexylamine (10.4g) and stirred at 0°C whereupon the salt precipitated. This was isolated by filtration and washed with hexane and dried to give pure 1-benzyl 2-benzylidene succinate dicyclohexylammonium salt (21.24g, 78% yield). This benzylidene compound (20g) was place in a Fisher-Porter bottle and also added were degassed methanol (200mL) and rhodium (R,R)DiPAMP (600mg) catalyst. The bottle was sealed and flushed with nitrogen then hydrogen. The reaction was hydrogenated at 40 psig for 15 hours at room temperature. The contents were then poured into a round bottom flask (500mL) and the solvent evaporated to give a dark solid. The residue was taken up in boiling isoctane and allowed to stand, with some title compound crystallizing (7.34g). The non-dissolved residue was taken up in boiling dimethoxyethane. This solution was allowed to cool for 12 hours, whereupon crystals of the title compound formed (6.05g). Combining the two crops gave 13.39g, 66% yield, mp 122-125°C. 300 MHz ¹H NMR: consistent with proposed structure.

2R-Benzyl butanedioic acid, 1-benzyl ester

The title compound of Step 11 (9.3g) was suspended in a mixture of water (84mL) and methanol (8.5mL). Solid sodium bisulfate (6.12) was added and the mixture stirred for 5 minutes. The mixture was extracted

with methylene chloride and the combined extracts were dried over magnesium sulfate and evaporated to dryness. The residue was chromatographed on silica gel, eluting with methanol-chloroform-acetic acid (5:95:0.5), to give 5 the pure title compound (4.3g, 74% yield).

Step 13

Benzyl αR-[2-[[2-(dimethylamino)ethyl]methylaminol]-2-
10 oxoethylbenzene propanoate

The title compound of Step 12 (4.3g) was dissolved in methylene chloride (20mL) and N-methyl piperidine (1.86g) was added. The mixture was cooled to 15 0°C and isobutylchloroformate (1.97g) was added. The mixture was stirred for 10 minutes whereupon N,N,N'-trimethylethylene diamine (2.23g) in methylene chloride (10mL) was added. This mixture was stirred at 4°C for 3 hours, then washed with 1N citric acid, saturated aqueous 20 sodium bicarbonate, water and brine. The solvent was evaporated to give the title compound (4.7g, 85% yield). 300 MHz ^1H NMR: consistent with proposed structure.

Step 14

αR-[2-[[2-(dimethylamino)ethyl]methylaminol]-2-
25 oxoethylbenzene propanoic acid

The title compound of Step 13 (4.6g) was 30 dissolved in ethanol (50mL) and hydrogenated over 4% Pd-C at 5psi at room temperature for 17 hours. The ethanol was evaporated to give the title compound (3g, 71% yield). 300 MHz ^1H NMR: consistent with proposed structure.

St p 15

O-(N-(dimethylaminoethyl)-N-methyl-aminocarbonyl)-3-L-phenyllactic acid

5

Benzyl L-3-phenyllactate (14.28g) was dissolved in tetrahydrofuran (357 mL) and to this was added carbonyl diimidazole (9.78g) and the mixture was stirred at room temperature for 4 hours. N,N,N'-trimethylene diamine (6.8g) was added and the mixture stirred for 8 hours. The solvent was evaporated and the residue taken up in ether and washed with water, dried over magnesium sulfate and evaporated to give a yellow oil (13g, 61% yield); 300 MHz ^1H NMR consistent with proposed structure. This ester was hydrogenated over 4% Pd-C @ 5psi and room temperature for 3.5 hours in tetrahydrofuran. The title compound was obtained as a white solid (10g) and recrystallized from methanol.

Anal. calcd for C₁₅H₂₂N₂O₄ + H₂O: C, 57.68;


20 H, 7.75; N, 8.98. Found: C, 57.60; H, 7.82; N, 8.94.

0
9
9
8
7
6
5
4
3
2
1
0

The following working Examples are provided to illustrate synthesis of Compounds 1-99 of the present invention and are not intended to limit the scope thereof. Those skilled in the art will readily understand that known variations of the conditions and processes of the following preparative procedures can be used to prepare the compounds of the Examples. All 25 temperatures expressed are in degrees Centigrade.

30

Example 1



5


N1-[1R*-[[[1S,1R*-(cyclohexylmethyl)-2S*,3R*-dihydroxyhexynylaminolcarbonyl]-3-butynyll-N4-[2-(dimethylamino)ethyl]-N4-methyl-2S*-(phenylmethyl)butanediamide

10

The title compound of Step 14 (0.109g) was dissolved at room temperature in dimethylformamide (2mL) and to this was added N,N'-disuccinimidyl-carbonate (0.96mg), pyridine (148mg) and dimethylaminopyridine (5mg in 0.5mL dimethylformamide). The mixture was stirred for 2 hours, whereupon the title amine of Step 10 (0.12g) was added as a solid in one portion. This mixture was allowed to stir for 12 hours. The solvent was evaporated and the residue dissolved in ethyl acetate. This mixture was washed successively with 5% potassium carbonate, water and brine, then dried over sodium sulfate and the solvent evaporated to afford the title compound (69mg, 31% yield).

Proton NMR spectrum: consistent with proposed structure.

Example 2



5

[1R*-][[1R*-[[1S,1R*-(cyclohexylmethyl)-2S*,3R*-
dihydroxy-hexynylaminolcarbonyl-3-
butynylaminolcarbonyl-2-phenylethyl][2-
(dimethylamino)ethylmethylcarbamate

The title acid of Step 15 is coupled to the title amine of Step 10 using the procedure described for the preparation of Example 1. The crude product is purified by flash chromatography on silica gel, eluting with chloroform-ethanol-ammonium hydroxide (84:15:1), to give title compound.

20


Compounds #3-99, as shown in Table I below, may be synthesized by reference to the foregoing specific and general procedures for preparing compounds of Formula I.

TABLE I


Example
Compound No.

Structure


3



4



5






09996345 • 112824

TABLE I

Example
Compound No.

Structure



卷之三

TABLE I

Example
Compound No.



Structure

TABLE I

Example
Compound No.

Structure


09996345-4113-01

TABLE I


Example
Compound No.

Structure


16




17



18



19




099963-145-1112321

TABLE I


Example
Compound No.

Structure


20




21



22



23




DRAFTS & REVISIONS - 11/2001

TABLE I


Example
Compound No.

Structure


24




25



26



27




09996345 - 143201

TABLE I


Example
Compound No.

Structure


28



29



30




0996375 - 112304

TABLE I


Example
Compound No.

Structure


31



32



33



09996345 - 112801

TABLE I

Example
Compound No.

Structure






TABLE I

Example
Compound No.

Structure






TABLE I

Example
Compound No.



Structure

TABLE I

Example
Compound No.

Structure


TOESEN - STEREOISOMERS

TABLE I


Example
Compound No.

Structure


46



47



48



0-267671-A2809

TABLE I

Example
Compound No.

Structure

49

50


51

TABLE I


Example
Compound No.

Structure


52



53



54




09596345 2123601

TABLE I


Example
Compound No.

Structure


55



56



57




ORGANIC CHEMISTRIES • INSTITUTE

TABLE I


Example
Compound No.

Structure

58



59



60





TABLE I


Example
Compound No.

Structure


61




62



63



64




DRAFT EDITION - 12/2001

TABLE I


Example
Compound No.

Structure

65



66




09998345 - 112604

TABLE I


Example
Compound No.

Structure

67



68



69







TABLE I - Synthesis of Compounds 67-69

TABLE I

Example
Compound No.




Structure

TOP SECRET • EDITION 06060

TABLE I

Example
Compound No.

Structure




09996245 * 1122604

TABLE I

Example
Compound No.

Structure




099962475 - 342804

TABLE I


Example
Compound No.

Structure


80




81



82



83.




059953-541-123201

TABLE I


Example
Compound No.

Structure


84




85



86



87




09996346 108201

TABLE I


Example
Compound No.

Structure


88




89



90



91




0099963455 = 4133901

TABLE I


Example
Compound No.

Structure


92



93



94



95




 09996345 - 12093
B08214

TABLE I


Example
Compound No.

Structure


96




97



98



99



0969634-412204

BIOLOGICAL EVALUATION**Human Renin Inhibition in vitro**

Compounds of Formula I were evaluated as inhibitors of human renin in an in vitro assay, as follows: This human renin inhibition test has been previously described in detail [Papaioannou et al., Clinical and Experimental Hypertension, A7(9), 1243-1257 (1985)]. Human renin was obtained from the National Institute for Biological Standards, London. An incubation mixture was prepared containing the following components: in a total volume of 0.25mL: 100 mM Tris-acetate buffer at pH 7.4, 25 x 10⁻⁶ Goldblatt units of renin, 0.05mL of plasma from human volunteers taking oral contraceptives, 6.0 mM Na-EDTA, 2.4 mM phenylmethyl sulfonyl fluoride, 1.5 mM 8-hydroxyquinoline, 0.4 mg/mL bovine serum albumin (BSA), and 0.024 mg/mL neomycin sulfate. This mixture was incubated for two hours at 37°C in the presence or absence of renin inhibitors. The produced angiotensin I was determined by radioimmunoassay (New England Nuclear kit). Test compounds to be assayed were dissolved in DMSO and diluted with 100mM Tris-acetate buffer at pH 7.4 containing 0.5% BSA to the appropriate concentration. The final concentration of organic solvent in the reaction mixture was less than 1%. Control incubations at 37°C were used to correct for effects of organic solvent on renin activity.

The in vitro enzymatic conversion of angiotensinogen to angiotensin I was inhibited by test compounds of the invention as indicated in Table II, below:

Table II

Human Renin in vitro Inhibition Data

5

Compound Example # IC50 Human Renin (nM)

Example 1 34

10

卷之三

**Marmoset Plasma Renin Activity (PRA) Inhibition
on Oral Administration**

The oral activity of renin inhibitor compounds
5 is determined in vivo in Marmoset monkeys using the
following procedure. Common Marmoset monkeys (*Callithrix*
jacchus, Charles River, both sexes, body weight 300-400g)
are placed on a modified high-protein low-sodium diet
(Purina, St. Louis, MO) for 1 week. About 24 hours prior
10 to the administration of test compound, Lasix (5mg/kg, im)
is given. On the day of the test, the animal is
anesthetized with isoflurane, body weight recorded, and a
baseline blood sample taken. Then, test compound is given
intragastrically and blood samples are taken in K-EDTA for
15 plasma renin activity at appropriate time intervals. The
PRA is determined by using the protocol outlined below.
Results may be expressed in terms of PRA at various time
intervals both before and after compound administrations.
It is expected that a compound of the invention, when
20 administered orally, would inhibit marmoset plasma renin
activity to a level of at about 70% at a dose of 20 mg/kg
of body weight.

PLASMA RENIN ACTIVITY ASSAY**I. Angiotensin I Generation**

5 Plasma Sample 200 ul
 PMSF 5% 1 ul
 Neomycin 10% 3 ul
 8-HQ 0.5M 3 ul
 TES 0.5M, pH 7.4 20 ul

10 25 ml of the above reaction mixtures, in duplicate, are
 incubated at 37°C or 0°C for 2 hours.

15 **II. Determination of Angiotensin I Concentrations**

Angiotensin I (AI) concentrations are determined
by radioimmunoassays with a commercial kit from NEN Co.

20 **III. Calculation of Plasma Renin Activity**

$$\text{PRA (ng AI/ml/hr)} = (\text{AI at } 37^\circ - \text{AI at } 0^\circ)/2 \text{ hr.}$$

25

Abbreviations used:

30

- PMSF : Phenylmethylsulfonylfluoride
8-HQ : 8-Hydroxyquinoline
BSA : Bovine Serum Albumin
TES : N-tris[Hydroxymethyl]methyl-2-aminoethane
 Sulfonic Acid
EDTA : Ethylenediamine Tetraacetic Acid

Determination of Oral Bioavailability

The bioavailability in marmosets and dogs is determined by sampling the blood via the femoral vein at various time points after administering the renin inhibitor compounds of the invention in polyethylene glycol 400 at an intragastric dose of 10 mg/kg or at an intravenous dose of 1 mg/kg. Compound concentration in plasma is determined using the bioassay technique described below. The percent bioavailability is calculated by dividing the area under the concentration-vs.-time curve obtained from the intragastric experiment by the area under the concentration-vs.-time curve obtained from the intravenous experiment (adjusting for different doses), and multiplying the result by 100%. A compound of the invention would be expected to be orally bioavailable in marmoset and dog.

OPPOSED - PCT/US01

Renin inhibitor plasma concentrations are determined by a bioassay. The plasma samples are extracted with acetonitrile and the extract is evaporated to dryness under nitrogen. Residue is dissolved in 4% bovine serum albumin containing 0.9% NaCl and 5% EDTA. The dissolved residue (0.1 ml) is incubated with a reaction mixture containing human plasma (0.12 ml), 5% phenylmethysulfonylfluoride (1.2 ul), 10% neomycin (2.4 ul), 0.5 M TES buffer (pH 7.4, 24 ul), and 0.6 mU/ml recombinant human renin (1000 U/mg, 50ul) at 37°C for 90 minutes. The renin activity is determined by a standard angiotensin I radioimmunoassay (New England Nuclear Corp.). The amount of test compound in the plasma is determined by comparing the extent of inhibition of renin activity with that produced by a known amount of test compound added to plasma and analyzed above.

Renin Inhibitor Species Specificity Method

Blood was collected in a 10 ml Becton Dickinson vacutainer tube with 0.1 ml of 15% EDTA (K3) solution (15 mg) from normal animals or high renin animals; i.e., those pre-treated with 5 mg/kg of Lasix® intramuscularly 2 times within a 6 hour interval 24 hours prior to bleeding. The blood was then centrifuged at 2500 RPM for 20 minutes and the plasma from the various species respectively pooled, aliquoted and stored in the freezer. The human plasma source was a male Caucasian taking a prescription of an angiotensin converting enzyme inhibitor.

The plasma renin activity assay is a modification of the human renin inhibition test in that the animal plasma is the source of both the renin substrate and the renin enzyme. In a total volume of 0.1 ml, 90 mM Tris-acetate buffer, pH 7.5, 12 mM sodium EDTA, 0.012 mg/ml neomycin sulfate, 0.9 mg/ml bovine serum albumin, 1.61 mM phenylmethyl sulfonyl fluoride, 4 mM 8-hydroxyquinoline and 0.09 ml of the animal or human plasmas were incubated for 2 hours at 37°C in a shaking water bath or at 4°C in an ice bath in the presence or absence of renin inhibitors. The produced angiotensin I was determined by radioimmunoassay (New England Nuclear kit).

The amount of angiotensin I generated during the 2 hours at 4°C was usually less than 5% of that activity produced at 37°C; however, the 4°C background values were nevertheless subtracted from the 37°C ones for the 100% activity values. The renin inhibitors are assayed in duplicate using 5 concentrations and the data is expressed as a percent of the 100% total renin activity.

**The Effect of Compound of the Invention on Marmoset
Blood Pressure Reduction on Intravenous
Administration**

5 The blood pressure reducing activity of the renin inhibitor compound of the invention is determined in vivo in Marmoset monkeys using the following procedure. Common Marmoset monkeys (*Callithrix jacchus*, Charles River, both sexes, body weight ca. 400g) were placed on a

10 modified high protein low sodium diet (Purina, St. Louis, MO) for 1 week. 24 hours prior to the administration of test compound, Lasix (5mg/kg, im) was given. On the day of the test, the animal was anesthetized with isoflurane, body weight recorded, and the left femoral artery and vein were

15 catheterized. The animal is allowed to regain consciousness and the title compound of Example 1 (100 micrograms/kg) is administered intravenously in 0.1 mL/kg polyethylene glycol 400 at time zero. Mean arterial blood pressure (MABP) in mmHg is then recorded every ten minutes until 120 minutes. It is expected that a compound of the invention would lower blood pressure in salt-depleted, conscious marmosets.

20

CONFIDENTIAL

Also embraced within this invention is a class of pharmaceutical compositions comprising one or more compounds of Formula I in association with one or more non-toxic, pharmaceutically acceptable carriers and/or diluents and/or adjuvants (collectively referred to herein as "carrier" materials) and, if desired, other active ingredients. The compounds of the present invention may be administered by any suitable route, preferably in the form of a pharmaceutical composition adapted to such a route, and in a dose effective for the treatment intended.

Therapeutically effective doses of the compounds of the present invention required to prevent or arrest the progress of the medical condition are readily ascertained by one of ordinary skill in the art. The compounds and composition may, for example, be administered intravascularly, intraperitoneally, subcutaneously, intramuscularly or topically.

For oral administration, the pharmaceutical composition may be in the form of, for example, a tablet, capsule, suspension or liquid. The pharmaceutical composition is preferably made in the form of a dosage unit containing a particular amount of the active ingredient. Examples of such dosage units are tablets or capsules.

These may with advantage contain an amount of active ingredient from about 1 to 250 mg, preferably from about 25 to 150 mg. A suitable daily dose for a mammal may vary widely depending on the condition of the patient and other factors. However, a dose of from about 0.1 to 3000 mg/kg body weight, particularly from about 1 to 100 mg/kg body weight, may be appropriate.

The active ingredient may also be administered by injection as a composition wherein, for example, saline, dextrose or water may be used as a suitable carrier. A suitable daily dose is from about 0.1 to 100 mg/kg body weight injected per day in multiple doses depending on the

disease being treated. A preferred daily dose would be from about 1 to 30 mg/kg body weight. Compounds indicated for prophylactic therapy will preferably be administered in a daily dose generally in a range from about 0.1 mg to about 5 100 mg per kilogram of body weight per day. A more preferred dosage will be a range from about 1 mg to about 100 mg per kilogram of body weight. Most preferred is a dosage in a range from about 1 to about 50 mg per kilogram of body weight per day. A suitable dose can be 10 administered, in multiple sub-doses per day. These sub-doses may be administered in unit dosage forms. Typically, a dose or sub-dose may contain from about 1 mg to about 400 mg of active compound per unit dosage form. A more preferred dosage will contain from about 2 mg to about 200 15 mg of active compound per unit dosage form. Most preferred is a dosage form containing from about 3 mg to about 100 mg of active compound per unit dose.

The dosage regimen for treating a disease 20 condition with the compounds and/or compositions of this invention is selected in accordance with a variety of factors, including the type, age, weight, sex and medical condition of the patient, the severity of the disease, the route of administration, and the particular compound 25 employed, and thus may vary widely.

For therapeutic purposes, the compounds of this invention are ordinarily combined with one or more adjuvants appropriate to the indicated route of 30 administration. If administered per os, the compounds may be admixed with lactose, sucrose, starch powder, cellulose esters of alkanoic acids, cellulose alkyl esters, talc, stearic acid, magnesium stearate, magnesium oxide, sodium and calcium salts of phosphoric and sulfuric acids, 35 gelatin, acacia gum, sodium alginate, polyvinylpyrrolidone, and/or polyvinyl alcohol, and then tableted or encapsulated for convenient administration. Such capsules or tablets may

contain a controlled-release formulation as may be provided in a dispersion of active compound in hydroxypropylmethyl cellulose. Formulations for parenteral administration may be in the form of aqueous or non-aqueous isotonic sterile
5 injection solutions or suspensions. These solutions and suspensions may be prepared from sterile powders or granules having one or more of the carriers or diluents mentioned for use in the formulations for oral administration. The compounds may be dissolved in water,
10 polyethylene glycol, propylene glycol, ethanol, corn oil, cottonseed oil, peanut oil, sesame oil, benzyl alcohol, sodium chloride, and/or various buffers. Other adjuvants and modes of administration are well and widely known in the pharmaceutical art.

15 Although this invention has been described with respect to specific embodiments, the details of these embodiments are not to be construed as limitations.

P R O C E S S I O N A L